MTSR: Metsera, Inc. - Summary | Jitta

Metsera, Inc.

NASDAQ:MTSR

Notice
Stock data is unavailable or the company’s delisted.
Price
$70.50
Loss Chance
59.6%
n/aJITTA SCORE
100.00%Over Jitta Line
Jitta Ranking
Sorry, the data is not yet available for this stock.
HISTORICAL JITTA SCORE
Sorry, the data is not yet available for this stock.
Jitta Factors
Growth Opportunity (0)
Recent Business Performance (17)
Financial Strength (24)
Return to Shareholders (0)
Competitive Advantage (1)
Jitta Signs
Cash Conversion CycleLess than 30 days
Recent IPOLess than 3 years
Recent Business PerformanceEarning decline 89.22% in the last quarter (yoy)
Key Stats
Jitta Score
Jitta Line
n/a
100.00%
2.21
139.10%
3.05
206.56%
Biotechnology
5.50
51.70%
6.36
42.69%
6.93
32.12%
COMPANY DESCRIPTION
Metsera, Inc. operates as a clinical-stage biopharmaceutical company, develops injectable and oral nutrient stimulated hormone analog peptides to treat obesity and cardiometabolic diseases. It develops MET-097i and MET-233i for the treatment of obesity and overweight; MET-233i/MET-097i; and MET-002, MET-224o, MET-067i, and MET-034i to treat disorders, such as diabetes and obesity, as well as MET-815i to reduce weight or prevents weight gain. Metsera, Inc. was formerly known as PHP Newco 1, Inc. The company was incorporated in 2022 and is based in New York, New York. As of November 13, 2025, Metsera, Inc. operates as a subsidiary of Pfizer Inc.